Integra LifeSciences IART Gain/Loss on Asset Sales
Gain/Loss on Asset Sales at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnSaleOfPropertyPlantEquipment.
The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Integra LifeSciences's gain/loss on asset sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Integra LifeSciences's gain/loss on asset sales?
- Integra LifeSciences (IART) reported gain/loss on asset sales of -$90K in Q1 2026.
- How has Integra LifeSciences's gain/loss on asset sales changed year-over-year?
- Integra LifeSciences's gain/loss on asset sales increased by 81.8% year-over-year, from -$495K to -$90K.
- What is the long-term trend for Integra LifeSciences's gain/loss on asset sales?
- Over 3 years (2021 to 2024), Integra LifeSciences's gain/loss on asset sales has grown at a -100.0% compound annual growth rate (CAGR), from $41.8M to $0.
- What does gain/loss on asset sales mean?
- Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.